These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 32687639)
1. Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria. Mao M; Liu H; Yan S; Yuan Y; Liu R; Wu Y; Peng C; Li J; Chen X Allergy; 2021 Feb; 76(2):571-573. PubMed ID: 32687639 [No Abstract] [Full Text] [Related]
6. Children with chronic spontaneous urticaria: Recurrence after remission and its predictors. Özyılmaz-Bozat G; Şahiner ÜM; Buyuktiryaki B; Uysal-Soyer Ö; Şekerel BE J Allergy Clin Immunol Pract; 2020 Feb; 8(2):796-798.e1. PubMed ID: 31425834 [No Abstract] [Full Text] [Related]
7. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria. Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395 [TBL] [Abstract][Full Text] [Related]
8. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature. Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910 [TBL] [Abstract][Full Text] [Related]
9. Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. Pourali SP; Gutierrez Y; Kucharik AH; Rajkumar JR; Jones ME; Armstrong AW Int J Dermatol; 2022 Aug; 61(8):e308-e309. PubMed ID: 34370872 [No Abstract] [Full Text] [Related]
10. Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels. Baysak S; Sevim Kecici A; Dogan B Dermatol Ther; 2020 Jul; 33(4):e13663. PubMed ID: 32447802 [TBL] [Abstract][Full Text] [Related]
11. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria. Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979 [No Abstract] [Full Text] [Related]
12. Pityriasis rosea during omalizumab treatment for chronic spontaneous urticaria. Vaccaro M; Marafioti I; Cannavò SP; Ciccarese G; Drago F Dermatol Ther; 2020 Nov; 33(6):e14356. PubMed ID: 33009684 [TBL] [Abstract][Full Text] [Related]
13. The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria. Su O; Bahali AG; Onsun N Dermatol Ther; 2020 Nov; 33(6):e14192. PubMed ID: 32790183 [TBL] [Abstract][Full Text] [Related]
14. Comment on ''how does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?'': reply from author. Önder S; Ozturk M Cutan Ocul Toxicol; 2020 Mar; 39(1):73. PubMed ID: 31899976 [TBL] [Abstract][Full Text] [Related]
15. High-dose omalizumab use in patients with chronic spontaneous urticaria. Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293 [No Abstract] [Full Text] [Related]